SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
1. Biohaven is under investigation for potential securities violations. 2. Claims allege misleading statements about drug approvals and efficacy. 3. Stock price fell 19.53% following FDA's extended review announcement. 4. Legal options are being presented to investors who incurred losses. 5. Deadline for lead plaintiff role in class action is September 12, 2025.